Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 ConferenceDr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome SpectrumJune 20, 2025 9:00 AM EDT | Source: Thiogenesis Therapeutics, Corp.San Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare pediatric and ...

Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides UpdateJune 17, 2025 9:00 AM EDT | Source: Thiogenesis Therapeutics, Corp.San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation o ...

San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, announces that pursuant to the terms of the Company's Omnibus Equity Incentive Plan, on June 11, 2025, the Company's board of directors approved a total grant of 400,000 common share purchas ...

TETRA Oasis Total Desalination Solution (TDS) Receives 2025 Hart Energy Special Meritorious Engineering Award for Innovation THE WOODLANDS, Texas, June 10, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced today that it will host an Investor Day on Thursday, September 25, 2025, in the Siebert Hall at the New York Stock Exchange ("NYSE") in New York City. During the event, TETRA's executive team will provide investors, analysts, and stakeholders with a roadmap to ...

Summary of TETRA Technologies (TTI) Conference Call Company Overview - TETRA Technologies has been operating for over 40 years, providing diverse revenue streams from energy services and industrial chemicals across the United States and 23 other countries [3][4] - The company is recognized as an industry innovation leader, particularly in completion fluids, oil and gas water treatment, and water management services [4] Financial Performance - TETRA reported a strong first quarter with adjusted EBITDA margins of 36% for completion fluids and 13% for water and flowback services [5] - The industrial chemicals segment achieved its highest first-quarter revenue and adjusted EBITDA in history [5] - Trailing twelve months revenue reached $327 million, reflecting a nearly 50% growth since the second year of COVID in 2021 [7] - The company has a solid balance sheet with a leverage ratio of 1.5 times and no debt maturities until 2029 and 2030 [29] Market Position and Growth Strategies - TETRA is positioned in key markets, including deepwater and unconventional markets in North America, Latin America, and the Middle East [4] - The company is focusing on three emerging growth strategies: 1. **Electrolytes for Energy Storage**: TETRA has developed a zinc bromide-based electrolyte for long-duration energy storage, partnering with Eos Technologies [13][14] 2. **Produced Water Desalination**: The company is introducing a desalination solution for produced water, targeting markets such as agriculture and industry [18][20] 3. **Critical Minerals Production**: TETRA has secured over 40,000 acres of brine leases in Arkansas, rich in lithium, bromine, magnesium, and manganese [22][24] Industry Trends and Challenges - The deepwater market is projected to grow at a 7% CAGR through 2028, with TETRA maintaining a strong market share [9] - The company is addressing challenges in the Permian Basin, where produced water disposal capacity is becoming limited, necessitating innovative solutions [19][20] - TETRA's technology investments are expected to enhance margins and operational efficiency, particularly in the water and flowback segment [11][12] Key Collaborations and Innovations - TETRA has collaborated with EOG Resources for produced water beneficial reuse and desalination pilot projects, achieving a 92% desalination rate in initial tests [21][20] - The company is leveraging automation technologies to reduce manpower requirements in operations, enhancing efficiency [12] Conclusion - TETRA Technologies is well-positioned for growth with a solid financial foundation, innovative technologies, and strategic partnerships, despite facing industry challenges [30]

Company Overview - TETRA Technologies, Inc. is an energy services and solutions company focused on environmentally conscious services and solutions [3] - The company operates on six continents and has a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [3] - TETRA provides products and services to the oil and gas industry and calcium chloride for various applications, while also expanding into the low-carbon energy market [3] Investor Conferences - TETRA's senior management will participate in two investor conferences in early June, including the Stifel 2025 Boston Cross Sector 1x1 Conference on June 4 [2] - CEO Brady Murphy and CFO Elijio Serrano will host one-on-one meetings with institutional investors at the Stifel conference [2] - VP of Investor Relations Kurt Hallead will also host one-on-one meetings at the RBC 2025 Capital Markets Global Energy, Power & Infrastructure Conference on June 4 [2]

Company Overview - TETRA Technologies, Inc. is an energy services and solutions company focused on environmentally conscious services and solutions that enhance quality of life [3] - The company operates on six continents and has a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [3] - TETRA provides products and services to the oil and gas industry and calcium chloride for various applications, while also expanding into the low-carbon energy market [3] Upcoming Event - TETRA's senior management will participate in the Virtual Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - Key executives including the CEO, CFO, and VP of Investor Relations will present and host one-on-one meetings with institutional investors [1] - A webcast of the event will be streamed at 1:15 pm ET on May 29, with a replay available the following day [2]

Core Insights - Thiogenesis Therapeutics has initiated a Phase 2 clinical trial for TTI-0102, targeting the treatment of MELAS, an inherited mitochondrial disease [1][3] - The trial aims to assess the safety, tolerability, efficacy, and pharmacokinetics of TTI-0102 over a 6-month period, involving 12 patients [2][3] - TTI-0102 is designed to increase intracellular antioxidants and amino acids, addressing deficiencies in MELAS patients [3][8] Company Overview - Thiogenesis Therapeutics is a clinical-stage biotechnology company based in San Diego, focusing on developing disulfides that enhance intracellular antioxidant production [1][10] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with a focus on treating serious pediatric diseases with unmet medical needs [10] Clinical Trial Details - The Phase 2 trial is a multi-country, multi-center study conducted in the Netherlands and France, with a randomized, double-blind, placebo-controlled design [2] - A total of 12 patients will be enrolled, with 8 receiving TTI-0102 and 4 receiving a placebo, followed by an interim analysis after 3 months [2] Disease Background - MELAS is characterized by symptoms such as seizures, muscle weakness, and fatigue, often presenting before the age of 20, and is caused by mitochondrial DNA mutations [4] - The disease affects approximately 4.1 per 100,000 of the population, making it one of the most prevalent inherited mitochondrial disorders [4] Product Information - TTI-0102 is an asymmetric disulfide and prodrug that acts as a precursor to cysteamine, aimed at restoring mitochondrial function by increasing levels of glutathione and taurine [8] - The prodrug formulation addresses limitations of first-generation thiol-based drugs, including short half-life and adverse side effects [8][9]

Group 1 - TETRA Technologies, Inc. will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City [1] - Senior management, including the CEO, CFO, and VP of Investor Relations, will host one-on-one meetings with institutional investors during the conference [1] - Investors interested in scheduling meetings can contact the company directly [2] Group 2 - TETRA Technologies, Inc. is an energy services and solutions company focused on environmentally conscious services [2] - The company operates on six continents and has a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [2] - TETRA is expanding into the low-carbon energy market, leveraging its chemistry expertise and global infrastructure to meet sustainable energy demands [2]

Financial Data and Key Metrics Changes - The company reported a record first quarter adjusted EBITDA of $32.3 million, with adjusted EBITDA margins of 20.5% [5] - Total revenue reached $157 million, reflecting a 17% sequential increase and a 4% year-over-year increase [5] - Adjusted EBITDA increased by 41% sequentially and year-over-year [5] Business Line Data and Key Metrics Changes - The Completion Fluids and Products segment generated $93 million in revenue, a 35% sequential increase, with adjusted EBITDA of $33.2 million, up 77% sequentially [20] - The Water and Flowback Services segment saw revenue decline by 2% sequentially to $64 million, but it was up 13% year-over-year, with adjusted EBITDA of $8.3 million [20][21] Market Data and Key Metrics Changes - Offshore deepwater operations increased by 60% year-over-year, with 24 deepwater projects completed in the quarter compared to 15 in the same period last year [6] - The company noted a decline in U.S. Frac activity by approximately 10%, but the Water and Flowback Services segment outperformed this decline [8] Company Strategy and Development Direction - The company is focusing on emerging growth initiatives, including desalination of produced water and energy storage solutions [12][14] - The Arkansas Evergreen Brine Production Unit expansion was approved, allowing for optimization of bromine and lithium extraction [15][16] - The company plans to self-fund its bromine project without issuing equity or increasing debt [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong second quarter outlook despite macroeconomic uncertainties [28] - The company anticipates adjusted EBITDA guidance for the first half of 2025 to be between $57 million and $65 million, up from the previous range [11] - Management highlighted the importance of monitoring customer plans and activity levels in response to the uncertain oil price environment [11] Other Important Information - The company generated strong free cash flow in the first quarter, with a year-over-year improvement of $41 million [12] - Liquidity at the end of the quarter was approximately $219 million, with a net leverage ratio improvement to 1.5 times [24] Q&A Session Summary Question: What are the biggest holdups for prospective customers on Oasis commercial pilots? - Management indicated that customers need to be comfortable with the technology and evolving environmental regulations, with expectations for multiple pilot projects in 2026 [33][34] Question: Can you provide specifics on regulatory support for beneficial reuse? - Management noted engagement with the Texas Railroad Commission and legislative support for surface discharge and beneficial reuse of produced water [35][36] Question: Will the first production well for Evergreen be left uncompleted until the processing facility is ready? - Management confirmed that the first well will be drilled and put on standby until the processing facility is operational [39] Question: What is the outlook for the deepwater market compared to previous quarters? - Management stated that there have been no changes to scheduled deepwater projects for the year, despite some uncertainty in the market [99][100]